Skip to main content
. 2015 Jan;104(1):32–43. doi: 10.5935/abc.20140173

Figure 2.

Figure 2

Cost-effectiveness acceptability curves of the five base-case scenarios (secondary and primary prevention, with ten-year risks ranging between 5% and 20% in the latter) and of the 5% ten-year risk primary prevention alternative scenario with statin prices fixed at the retail sales prices of the drugs.